期刊文献+

人巨细胞病毒包膜糖蛋白B线性B细胞抗原表位的预测 被引量:2

B cell line epitopes prediction of human cytomegalovirus glycoprotein B
分享 导出
摘要 目的 通过生物信息学方法分析人巨细胞病毒(human cytomegalovirus,HCMV)包膜糖蛋白B(glycoprotein B,g B)的结构及理化特性,预测g B的线性B细胞抗原表位。方法基于HCMV g B的序列,利用两种在线B细胞表位预测程序及DNAstar软件对g B进行预测;利用SWISS-MODEL服务器同源构建g B三级结构模型,进行进一步验证。结果与结论综合多项分析,预测得到HCMVg B的多个线性B细胞表位,为后续验证其优势中和表位,建立富含高效价中和抗体的原料血浆的筛选方法奠定了基础。 Objective To predict the B cell line epitopes of human cytomegalovirus glycoprotein (gB)by analyzing its structure and physicochemical properties using bioinformatics approaches. Methods Based on the sequence of the HCMV gB,the probable B cell epitopes are predicted using two online prediction programs and DNAstar software. Meanwhile, the tertiary structure of gB was constructed by homologous modeling with the assistance of SWISS-MODEL server to rule out impossible B cell epitopes. Results and Conclusion The B cell line epitopes of gB are predicted, which provides a theoretical basis for further verification of gB immunodominant epitopes and screening the source plasma with high HCMV IgG titer.
作者 闫晶晶 吕茂民 赵雄 尹惠琼 章金刚 YAN,Jing-jing, LU Mao-min,ZHAO Xiong,YIN Hui-qiong,ZHANG Jin-gang (1. Guangxi Medical University, Nanning 530021, China; 2. Laboratory for Viral Safety, National Center of Biomedical Analysis, Institute of Transfusion Medicine, Academy of Military Medical Sciences, Beijing 100850, China)
出处 《军事医学》 CAS CSCD 北大核心 2015年第3期184-188,共5页 Military Medical Sciences
基金 国家863计划资助项目(2012AA021902)
关键词 人巨细胞病毒 糖蛋白B B细胞表位 human cytomegalovirus glycoprotein B B cell epitopes
作者简介 [通讯作者]章金刚,E-mail:zhangjg@bmi.ac.cn; 吕茂民,E-mail:maominlv@126.com
  • 相关文献

参考文献22

  • 1Fang FQ,Fan QS,Yang ZJ,et al. Incidence of cytomegalovirusinfection in Shanghai,China[J]. Clin Vaccine Immunol, 2009,16(11): 1700-1703. 被引量:1
  • 2林琼琳,郭雅春,彭燕,章霞,徐晶心,郑全荣,段琼琼,刘勇,焦万国.南昌地区供受血者巨细胞病毒感染情况调查及相关性研究[J].临床血液学杂志:输血与检验,2013(2):273-274. 被引量:5
  • 3Adler SP, Nigro G, Pereira L. Recent advances in the preventionand treatment of congenital cytomegalovirus infeotions[ J] ? SeminPerinatol, 2007, 31(1): 10-18. 被引量:1
  • 4Zhong J, Rist M, Cooper L, et al. Induction ctf pluripotent proteo-tive immunity following immunisation with a chimeric vaccine againsthuman cytome^lovirus[J]. PI-oS Oie, 2008, 3(9) : e3256. 被引量:1
  • 5Akinbami AA, Rabiu KA,Adewunmi AA,et al. Seroprevalenceof cytomegalovirus antibodies amongst normal pregnant women inNigeriaf J] . Int J Womens Health,2011,3 : 423 -428. 被引量:1
  • 6向思龙,马玉媛,余蓉,章金刚.防治人巨细胞病毒感染的抗体类药物[J].国际药学研究杂志,2013(1):33-38. 被引量:6
  • 7Navarro D, Lennette E, Tugizov S, et al. Humoral immune re-sponse to functional regions of human cytomegalovirus glycopro-tein B[J]. J Med Virol, 1997, 52(4) : 451 -459. 被引量:1
  • 8Britt WJ, Vugler L, Butfiloski EJ, et al. Cell surface expressionof human cytomegalovirus ( HCMV ) gp55-l 16 ( gB ) : use ofHCMV-recombinant vaccinia virus-infected cells in analysis of thehuman neutralizing antibody response [ J]. J Virol, 1990, 64(3) : 1079 -1085. 被引量:1
  • 9Hwang ES, Kwon KB, Park JW, et al. Induction of neutralizingantibody against human cytomegalovirus ( HCMV) with DNA-me-diated immunization of HCMV glycoprotein B in mice[ J ]. Micro-biol Immunol, 1999, 43(3) : 307 -310. 被引量:1
  • 10Endresz V,Kari L, Berencsi K, et al. Induction of human cyto-megalovirus (HCMV ) -glycoprotein B ( gB ) -specific neutralizingantibody and phosphoprotein 65 ( pp65) -specific cytotoxic T lym-phocyte responses by naked DNA immunization [ J ] . Vaccine,1999, 17(1) : 50-58. 被引量:1

二级参考文献65

  • 1何玲,邓莉莉.恶性血液病患者并发病毒感染的临床研究[J].现代诊断与治疗,2004,15(5):281-282. 被引量:2
  • 2陈俊青,刘霆.巨细胞病毒感染检测方法的现况和进展[J].中国输血杂志,2005,18(5):428-431. 被引量:15
  • 3Ksiazek TG,Erdman D,Goldsmith CS,et al.SARS Working Group.A novel coronavirus associated with severe acute respiratory syndrome[J].N Engl J Med,2003,348(20):1953. 被引量:1
  • 4Pratelli A,Tinelli A,Decaro N,et al.Safety and efficacy of a modified-live canine coronavirus vaccine in dogs[J].Vet Microbiol,2004,99 (1):43. 被引量:1
  • 5Rota PA,Oberste MS,Monroe SS,et al.Characterization of a novel coronavirus associated with severe acute respiratory syndrome[J].Science, 2003,300(5624):1394. 被引量:1
  • 6Gallagher TM,Buchmeier MJ.Coronavirus spike proteins in viral entry and pathogenesis[J].irology,2001,279(2):371. 被引量:1
  • 7Li W,Moore MJ,Vasilieva N,et al.Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus[J].Nature,2003,426(69 65):450. 被引量:1
  • 8Wong SK,Li W,Moore MJ,et al.A 193-amino acid fragment of the SARS coronavirus Sprotein efficiently binds angiotensin-converting enzyme 2[J].J Biol Chem,2004,279(5):3197. 被引量:1
  • 9Boeckh M,Geballe AP. Cytomegalovirus:pathogen,paradigm,and puzzle[J].Journal of Clinical Investigation,2011,(05):1673-1680. 被引量:1
  • 10Fannin Rider PJ,Dunn W,Yang E. Human cytomegalovirus microRNAs[J].Current Topics in Microbiology and Immunology,2008.21-39. 被引量:1

共引文献11

同被引文献43

  • 1鲁毅,李任峰,徐萍,李学斌,王三虎.来航鸡FOXL2蛋白的生物信息学分析[J].生物技术,2012(2):43-46. 被引量:5
  • 2吴玉章,朱锡华.一种病蛋白B细胞表位预测方法的建立[J].科学通报,1994,39(24):2275-2279. 被引量:66
  • 3Bruni L, Barrionuevo-Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre ). Human papillomavirus and related diseases in the world. Summary report 2015 - 12 - 23. (2015 - 12 - 23 ) [ 2015 - 12 - 25 ]. http ://www. hpvcentre, net/statistics/reports/XWX, pdf. 被引量:1
  • 4Hassan S W, Waheed M T, Miller M, et al. Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: an approach for a capsomere-based HPV vaccine [ J ]. Hum Vaccine Immunother, 2014, 10 (10) : 2975 - 2982. 被引量:1
  • 5NO authors listed. Human papillomavirus vaccines: WHO position paper, October 2014-Recommendations [ J ]. Vaccine, 2015, 33(36) : 4383 -4384. 被引量:1
  • 6Parkin D M. Global cancer statistics in the year 2000 [ J ]. Lancet Oncol, 2001, 2(9): 533-543. 被引量:1
  • 7Schiller J T, Castellsagu6 X, Garland S M. A review of clinical trials of human papillomavirus prophylactic vaccines[J]. Vaccine, 2012, 30:F123 - F138. 被引量:1
  • 8Herrere R, Gonzalez P, Markowitz L E. Present status of human papillomavirus vaccine development and implementation [ J/OL ]. Lancet Oncol, 2015, 16(5) : e206 - e216. doi: 10. 1016/S1470 - 2045( 14)70481 -4. 被引量:1
  • 9Schiller J T, Mttller M. Next generation prophylactic human papillomavirus vaceines[J/OL]. Lancet Oncol, 2015, 16(5): e217- e225. doi: 10. 1016/S1470 -2045( 14)71179 -9. 被引量:1
  • 10Guan J, Bywaters S M, Brendle S A, et al. Structural comparison of four different antibodies interacting with human papillomavims 16 and mechanisms of neutralization [ J]. Virology, 2015, 483 : 253 - 263. 被引量:1

引证文献2

二级引证文献8

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈